Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Adenocarcinoma 2Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × technetium 99m etarfolatide × Clear all
NCT01577654 2021-04-01

TARGET

Endocyte

Phase 2 Completed
203 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00511485 2015-02-27

Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03)

Endocyte

Phase 2 Completed
43 enrolled
Thoracic

Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01953536 2014-12-19

Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

Endocyte

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡